-
Medicaid managed care plans currently serve 21.6 million people, and this number is expected to increase significantly as a result of the health care reform legislation.
-
This story is the second of a two-part series on improving care of high-risk youth enrolled in Medicaid. This month, we examine the impact of improved quality on subsequent contacts with the juvenile justice system.
-
A "master planning" approach is needed to effectively leverage all of the incentives and resources for building statewide Health Information Exchange (HIE) capacity, says Lynn Dierker, RN, project director for the Chicago-based AHIMA Foundation's state-level HIE Consensus Project.
-
Athos Alexandrou, director of Maryland's Medicaid pharmacy program, says the state will benefit fiscally from the health care reform legislation's drug rebate program, by getting a share of rebates for pharmaceuticals dispensed by managed care organizations (MCOs). On the other hand, money will be lost on the fee-for-service side.
-
Like many state Medicaid directors, Elena Nicolella says that her biggest fiscal challenge is responding to an ever-increasing need for services with an ever-decreasing amount of revenue.
-
Much of the hotly debated health care reform legislation won't actually be implemented for months or years, but an expanded drug rebate program is an important exception. States can collect additional rebates right away, which may help some with severe budget shortfalls.
-
An approach designed to reduce HIV and sexually transmitted diseases (STDs) in adolescents previously used exclusively by academic researchers now has been shown to be successfully implemented by community-based organizations (CBOs).
-
An analysis presented at the 2010 National STD Prevention Conference gives a chilling look at impact of HIV and syphilis among U.S. gay and bisexual men.
-
Several descriptive phrases are now being coined when family planning providers discuss such highly effective reversible methods as intrauterine contraception (ParaGard Copper T 380A intrauterine device, Duramed Pharmaceuticals, and the Mirena levonorgestrel intrauterine system, Bayer HealthCare Pharmaceuticals) and the contraceptive implant (Implanon, Schering-Plough Corp.).
-